← Eichor
Study identifier: NCT04135664 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma

Condition: Esophageal Cancer  ·  Sponsor: Shanghai Chest Hospital

PhasePhase 3
Planned participants176
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

The ad-ESD trial is phase III randomized trial to compare adjuvant esophagectomy and chemoradiation for patients with clinical stage N0 and pathological stage T1b squamous cell carcinoma (after endoscopic submucosal dissection).

This description comes directly from the study's public registry record.

Talk to the study team

Zhigang Li, MD  ·  18960619260  ·  dr_lizhigang@163.com

Xiaobin Zhang, MD  ·  18516302162  ·  zxb5212@163.com

Always discuss trial participation with your own doctor first.

Locations (6)

The First Affiliated Hospital of Nanchang UniversityNanchang, Jiangxi, ChinaActive Not Recruiting
Changhai Hospital, The Second Military Medical UniversityShanghai, ChinaActive Not Recruiting
Ruijin Hospital, Shanghai Jiao Tong University, School of MedicineShanghai, ChinaActive Not Recruiting
Shanghai Chest Hospital, Shanghai Jiao Tong UniversityShanghai, ChinaRecruiting
Zhongshan Hospital, Fudan UniversityShanghai, ChinaActive Not Recruiting
Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaActive Not Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04135664